Physician profile
Mary Glover
NPI 1720309941
$10,319.90
in general payments reported to CMS, 2019-2025
33 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,449 · 2020: $750 · 2021: $1,572 · 2022: $1,706 · 2023: $1,664 · 2024: $1,773 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,594 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,594.17 |
| Education | $248.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,140.88 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,008.38 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $981.51 | 2019-2025 | Ilumya |
| Pfizer INC. | $880.89 | 2019-2025 | |
| Galderma Laboratories, L.P. | $713.80 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Regeneron Healthcare Solutions, INC. | $582.38 | 2019-2023 | Libtayo |
| Lilly USA, LLC | $476.74 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $429.44 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $319.60 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $307.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $301.37 | 2019-2025 | |
| Incyte Corporation | $294.35 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $291.27 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $289.61 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Amgen INC. | $272.85 | 2020-2024 | Otezla, Enbrel |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $117.13 | 2023-2025 | Zoryve |
| Almirall LLC | $116.82 | 2021-2023 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $111.87 | 2019-2023 | Valchlor |
| Genentech USA, INC. | $105.58 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $103.84 | 2019-2023 | |
| Celgene Corporation | $73.41 | 2019 | |
| Kerecis Limited | $65.45 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Paratek Pharmaceuticals, INC. | $58.64 | 2021-2022 | |
| Epi Health, LLC | $56.12 | 2021-2022 | |
| Organogenesis INC. | $46.67 | 2023-2024 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.81 | 2022-2024 | Spevigo |
| Journey Medical Corporation | $36.24 | 2022 | |
| Verrica Pharmaceuticals INC. | $22.29 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $17.26 | 2023 | Vtama |
| Botanix Sb INC | $15.18 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $14.48 | 2024 | Xtrac |
| Pierre Fabre Pharmaceuticals, INC. | $14.35 | 2020 | |
| Allergan, INC. | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.